Category Archives: ASP3026 from Astellas

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Phase 1 trial of ASP3026

The first posting about this Phase 1 trial in ClinicalTrials.gov was in 1-25-2011. The trial number is NCTO1284192. It was conducted at 6 hospitals. On March 10, 2016 an article was published that said the dose escalation part of trial … Continue reading

Posted in ASP3026 from Astellas, Lung cancer, Potential Treatments, Research | Leave a comment

Effectivness of certain 2nd generation ALK inhibitors against specific ALK mutations

Four 2nd generation ALK inhibitors (Ceritinib, Alectinib, AP26113, and ASP3026) were tested in vitro against six known mutations of the ALK fusion gene. Generally, AP26113 (brigatinib) was most effective and ASP3026 was least effective. In some cases one drug worked … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, ceritinib - Zykadia from Novartis, Lung cancer, Research, Resistance to treatment | Leave a comment

Treatment potential in Lymphomas

Effectivness of ASP3026 (which is no longer in clinical trials for this disease) was tested on NPM-ALK in lymphomas with positive results. http://impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=2170&path%5B%5D=3439

Posted in Anaplastic Large-Cell Lymphomas, ASP3026 from Astellas, Potential Treatments, Research | Leave a comment

Astellas discontinues research on ASP3026

http://www.astellas.com/en/ir/library/pdf/3q2014_rd_en.pdf See page 28

Posted in ASP3026 from Astellas, Potential Treatments | Leave a comment